Luke R G Pike1, Andrew Bang2, Brandon A Mahal3, Allison Taylor4, Monica Krishnan4, Alexander Spektor4, Daniel N Cagney4, Ayal A Aizer4, Brian M Alexander4, Osama Rahma4, Tracy Balboni4, Patrick A Ott4, F Stephen Hodi4, Jonathan D Schoenfeld4. 1. Brigham and Women's Hospital and Dana-Farber/Harvard Cancer Center, Boston, Massachusetts; Harvard Radiation Oncology Program, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: lrpike@partners.org. 2. Brigham and Women's Hospital and Dana-Farber/Harvard Cancer Center, Boston, Massachusetts; Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada. 3. Brigham and Women's Hospital and Dana-Farber/Harvard Cancer Center, Boston, Massachusetts; Harvard Radiation Oncology Program, Massachusetts General Hospital, Boston, Massachusetts. 4. Brigham and Women's Hospital and Dana-Farber/Harvard Cancer Center, Boston, Massachusetts.
Abstract
PURPOSE: Therapeutic radiation has conflicting immune effects: radiation therapy (RT)-induced immunogenic cell death can contribute to immune response, but lymphocytes are also sensitive to RT. It is unknown whether palliative RT leads to lymphopenia in patients treated with immune checkpoint inhibitors (ICIs) and whether this affects outcomes. As such, we sought to assess the impact of palliative RT on circulating lymphocyte count and neutrophil-to-lymphocyte ratio in patients being treated with PD-1-directed ICI and associations with survival. METHODS AND MATERIALS: We identified patients from 5 radiation oncology centers, treated with palliative RT and either pembrolizumab or nivolumab with non-small cell lung cancer, metastatic melanoma, and renal cell carcinoma. Patients who received intervening cytotoxic chemotherapy were excluded. We recorded absolute lymphocyte count (ALC) and neutrophil-to-lymphocyte ratio before and after palliative RT and at the start of ICI. Survival was analyzed using the Kaplan-Meier method and Cox proportional hazard models. RESULTS: One hundred ten patients received 225 courses of palliative RT. Median change in ALC after RT was -161 cells/mL. Decreases in ALC were greater with RT to the spine, lung/mediastinum, and chest wall compared with the brain, extremity, or abdomen/pelvis (P = .002) and after courses >5 fractions (P = .003). Extracranial and >5-fraction RT was associated with increased odds of severe lymphopenia (ALC <500) at the end of RT (odds ratio [OR], 3.7; P = .001; and OR, 3.9; P = .001, respectively). Patients who developed RT-induced severe lymphopenia were more likely to have severe lymphopenia when ICI was initiated (OR, 6.4; P = .0001), particularly when RT was administered in the previous 3 months (OR, 189; P < .0001). Severe lymphopenia at onset of ICI therapy was associated with increased mortality on multivariable analysis (hazard ratio, 2.1; P = .03). CONCLUSIONS: Extracranial or prolonged courses of RT increase the risk of severe lymphopenia, which is associated with poorer survival in patients treated with ICI.
PURPOSE: Therapeutic radiation has conflicting immune effects: radiation therapy (RT)-induced immunogenic cell death can contribute to immune response, but lymphocytes are also sensitive to RT. It is unknown whether palliative RT leads to lymphopenia in patients treated with immune checkpoint inhibitors (ICIs) and whether this affects outcomes. As such, we sought to assess the impact of palliative RT on circulating lymphocyte count and neutrophil-to-lymphocyte ratio in patients being treated with PD-1-directed ICI and associations with survival. METHODS AND MATERIALS: We identified patients from 5 radiation oncology centers, treated with palliative RT and either pembrolizumab or nivolumab with non-small cell lung cancer, metastatic melanoma, and renal cell carcinoma. Patients who received intervening cytotoxic chemotherapy were excluded. We recorded absolute lymphocyte count (ALC) and neutrophil-to-lymphocyte ratio before and after palliative RT and at the start of ICI. Survival was analyzed using the Kaplan-Meier method and Cox proportional hazard models. RESULTS: One hundred ten patients received 225 courses of palliative RT. Median change in ALC after RT was -161 cells/mL. Decreases in ALC were greater with RT to the spine, lung/mediastinum, and chest wall compared with the brain, extremity, or abdomen/pelvis (P = .002) and after courses >5 fractions (P = .003). Extracranial and >5-fraction RT was associated with increased odds of severe lymphopenia (ALC <500) at the end of RT (odds ratio [OR], 3.7; P = .001; and OR, 3.9; P = .001, respectively). Patients who developed RT-induced severe lymphopenia were more likely to have severe lymphopenia when ICI was initiated (OR, 6.4; P = .0001), particularly when RT was administered in the previous 3 months (OR, 189; P < .0001). Severe lymphopenia at onset of ICI therapy was associated with increased mortality on multivariable analysis (hazard ratio, 2.1; P = .03). CONCLUSIONS: Extracranial or prolonged courses of RT increase the risk of severe lymphopenia, which is associated with poorer survival in patients treated with ICI.
Authors: Alexander D Sherry; Rie von Eyben; Neil B Newman; Paulina Gutkin; Ingrid Mayer; Kathleen Horst; A Bapsi Chakravarthy; Marjan Rafat Journal: Int J Radiat Oncol Biol Phys Date: 2019-12-03 Impact factor: 7.038
Authors: Jonathan D Schoenfeld; Anita Giobbie-Hurder; Srinika Ranasinghe; Katrina Z Kao; Ana Lako; Junko Tsuji; Yang Liu; Ryan C Brennick; Ryan D Gentzler; Carrie Lee; Joleen Hubbard; Susanne M Arnold; James L Abbruzzese; Salma K Jabbour; Nataliya V Uboha; Kevin L Stephans; Jennifer M Johnson; Haeseong Park; Liza C Villaruz; Elad Sharon; Howard Streicher; Mansoor M Ahmed; Hayley Lyon; Carrie Cibuskis; Niall Lennon; Aashna Jhaveri; Lin Yang; Jennifer Altreuter; Lauren Gunasti; Jason L Weirather; Raymond H Mak; Mark M Awad; Scott J Rodig; Helen X Chen; Catherine J Wu; Arta M Monjazeb; F Stephen Hodi Journal: Lancet Oncol Date: 2022-01-13 Impact factor: 41.316
Authors: Flor Mendez; Padma Kadiyala; Felipe J Nunez; Stephen Carney; Fernando M Nunez; Jessica C Gauss; Ramya Ravindran; Sheeba Pawar; Marta Edwards; Maria Belen Garcia-Fabiani; Santiago Haase; Pedro R Lowenstein; Maria G Castro Journal: Clin Cancer Res Date: 2020-04-24 Impact factor: 12.531
Authors: Alexander J Lin; Margery Gang; Yuan James Rao; Jian Campian; Mackenzie Daly; Hiram Gay; Peter Oppelt; Ryan S Jackson; Jason Rich; Randal Paniello; Jose Zevallos; Dennis Hallahan; Douglas Adkins; Wade Thorstad Journal: JAMA Otolaryngol Head Neck Surg Date: 2019-05-01 Impact factor: 6.223
Authors: Clemens Grassberger; Susannah G Ellsworth; Moses Q Wilks; Florence K Keane; Jay S Loeffler Journal: Nat Rev Clin Oncol Date: 2019-06-26 Impact factor: 66.675
Authors: Jonathan Khalifa; Julien Mazieres; Carlos Gomez-Roca; Maha Ayyoub; Elizabeth Cohen-Jonathan Moyal Journal: Front Oncol Date: 2021-04-21 Impact factor: 6.244
Authors: Arta M Monjazeb; Anita Giobbie-Hurder; Ana Lako; Emily M Thrash; Ryan C Brennick; Katrina Z Kao; Claire Manuszak; Ryan D Gentzler; Anteneh Tesfaye; Salma K Jabbour; Olatunji B Alese; Osama E Rahma; James M Cleary; Elad Sharon; Harvey J Mamon; May Cho; Howard Streicher; Helen X Chen; Mansoor M Ahmed; Adrian Mariño-Enríquez; Seunghee Kim-Schulze; Sacha Gnjatic; Emanual Maverakis; Alina I Marusina; Alexander A Merleev; Mariano Severgnini; Kathleen L Pfaff; James Lindsay; Jason L Weirather; Srinika Ranasinghe; Alexander Spektor; Scott J Rodig; Stephen F Hodi; Jonathan D Schoenfeld Journal: Clin Cancer Res Date: 2021-02-10 Impact factor: 13.801